modelSpiramycinAndMetronidazo
Extends from Pharmacolibrary.Drugs.ATC.J.J01RA04.
Information
| name: | SpiramycinAndMetronidazole | |
| ATC code: | J01RA04 | route: | oral |
| compartments: | 1 | |
| dosage: | 1500 | mg |
| volume of distribution: | 60 | L |
| clearance: | 2 | L/h |
| other parameters in model implementation | ||
Spiramycin and metronidazole is a fixed-dose combination antibacterial medication used primarily for the treatment of mixed infections, especially dental and orofacial infections. Spiramycin is a macrolide antibiotic, while metronidazole is an antibiotic and antiprotozoal agent. The combination is approved in some countries but not all, and is not approved in the United States.
Pharmacokinetics
No published pharmacokinetic parameters for the combination product (spiramycin and metronidazole) are available. The following parameters are estimated based on separate pharmacokinetic data for the individual components in healthy adults after oral administration.
References
Isla, A, et al., & Pedraz, JL (2005). [Pharmacokinetic/pharmacodynamic analysis of antibiotic therapy in dentistry and stomatology]. Enfermedades infecciosas y microbiologia clinica 23(3) 116–121. DOI:10.1157/13072159 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15757581
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)